Not because people can’t disagree with my words, but because self-censorship driven by fear (Trump threatening to sue the BBC) should concern all of us. /3
Not because people can’t disagree with my words, but because self-censorship driven by fear (Trump threatening to sue the BBC) should concern all of us. /3
I was told the decision came from the highest levels within the BBC. /2
I was told the decision came from the highest levels within the BBC. /2
They deleted the line in which I describe Donald Trump as “the most openly corrupt president in American history.” /1
They deleted the line in which I describe Donald Trump as “the most openly corrupt president in American history.” /1
@wsj.com
www.wsj.com/world/russia...
@wsj.com
www.wsj.com/world/russia...
@wsj.com
www.wsj.com/world/russia...
@wsj.com
www.wsj.com/economy/cent...
@wsj.com
www.wsj.com/economy/cent...
@Kalshi shows the Fed governor with a slight lead over Hassett
kalshi.com/markets/k...
@Kalshi shows the Fed governor with a slight lead over Hassett
kalshi.com/markets/k...
(via Liz Ann Sonders)
(via Liz Ann Sonders)
@apnews.com
@apnews.com
“.. deceleration in the second derivative is partly what seems to be in the air right now. .. I still don’t want to fight the flow of capital .. but I’m lowering my expectations for how much this will excite the market on a going forward basis.” [Pasquariello]
Spending plans this holiday are increasingly bifurcated, with high-income consumers planning to spend more while low-income consumers plan to spend less.
Millennial and Gen Z consumers indicated more cautious holiday spending plans
Johnson had “cautioned the White House that most House Republicans don’t have an appetite for extending enhanced Affordable Care Act subsidies ..”
@wsj.com #ACA
www.wsj.com/politics/pol...
Johnson had “cautioned the White House that most House Republicans don’t have an appetite for extending enhanced Affordable Care Act subsidies ..”
@wsj.com #ACA
www.wsj.com/politics/pol...
*NOVO PHASE 2 WITH AMYCRETIN REPORTS `SIGNIFICANT' WEIGHT LOSS
*NOVO'S AMYCRETIN SHOWED WEIGHT LOSS OF UP TO 14.5% AT 36 WEEKS
*NOVO: AMYCRETIN APPEARED TO HAVE SAFE, WELL-TOLERATED PROFILE
*NOVO PHASE 2 WITH AMYCRETIN REPORTS `SIGNIFICANT' WEIGHT LOSS
*NOVO'S AMYCRETIN SHOWED WEIGHT LOSS OF UP TO 14.5% AT 36 WEEKS
*NOVO: AMYCRETIN APPEARED TO HAVE SAFE, WELL-TOLERATED PROFILE